Results 21 to 30 of about 63,987 (250)

A switching mechanism in doxorubicin bioactivation can be exploited to control doxorubicin toxicity.

PLoS Computational Biology, 2011
Although doxorubicin toxicity in cancer cells is multifactorial, the enzymatic bioactivation of the drug can significantly contribute to its cytotoxicity. Previous research has identified most of the components that comprise the doxorubicin bioactivation
Nnenna A Finn, Harry W Findley, Melissa L Kemp   +2 more
doaj   +1 more source

Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin

Biomolecules, 2022
Doxorubicin is the most frequently used chemotherapeutic agent for the treatment of hepatocellular carcinoma. However, one major obstacle to the effective management of liver cancer is the drug resistance derived from the cancer stem cells.
Wang Yin, Cuong V. Pham, Tao Wang, Hadi Al Shamaileh, Rocky Chowdhury, Shweta Patel, Yong Li, Lingxue Kong, Yingchu Hou, Yimin Zhu, Sunrui Chen, Huo Xu, Lee Jia, Wei Duan, Dongxi Xiang   +14 more
doaj   +1 more source

PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis

Current Problems in Cancer: Case Reports, 2020
Drug induced pancreatitis is rare and establishing the exact causal relationship is challenging. Here, we discuss the management of a 60 year-old female patient with stage 3a breast cancer who developed doxorubicin induced pancreatitis 3 days after her ...
Luke Ardolino, Eugene Moylan
doaj   +1 more source

Overexpressed SIRT6 ameliorates doxorubicin-induced cardiotoxicity and potentiates the therapeutic efficacy through metabolic remodeling

Acta Pharmaceutica Sinica B, 2023
Since the utilization of anthracyclines in cancer therapy, severe cardiotoxicity has become a major obstacle. The major challenge in treating cancer patients with anthracyclines is minimizing cardiotoxicity without compromising antitumor efficacy. Herein,
Kezheng Peng, Chenye Zeng, Yuqi Gao, Binliang Liu, Liyuan Li, Kang Xu, Yuemiao Yin, Ying Qiu, Mingkui Zhang, Fei Ma, Zhao Wang   +10 more
doaj   +1 more source

Efficient chemotherapy of rat glioblastoma using Doxorubicin-loaded PLGA nanoparticles with different stabilizers [PDF]

, 2011
Background: Chemotherapy of glioblastoma is largely ineffective as the blood-brain barrier (BBB) prevents entry of most anticancer agents into the brain.
Markus Glatzel, Kreuter, Jörg (Prof. Dr.), Christian Bernreuther, Olga Maksimenko, Maksimenko, Olga, Khalansky, Alexander S., Jörg Kreuter, Wohlfart, Stefanie, Gelperina, Svetlana, Svetlana Gelperina, Bernreuther, Christian, Stefanie Wohlfart, Alexander S Khalansky, Glatzel, Markus, Alexander S. Khalansky   +14 more
core   +2 more sources

Lipid Emulsion Inhibits the Late Apoptosis/Cardiotoxicity Induced by Doxorubicin in Rat Cardiomyoblasts

Cells, 2018
This study aimed to examine the effect of lipid emulsion on the cardiotoxicity induced by doxorubicin in H9c2 rat cardiomyoblasts and elucidates the associated cellular mechanism.
Raghavendra Baregundi Subbarao, Seong-Ho Ok, Soo Hee Lee, Dawon Kang, Eun-Jin Kim, Ji-Yoon Kim, Ju-Tae Sohn   +6 more
doaj   +1 more source

Exosomal Doxorubicin Reduces the Cardiac Toxicity of Doxorubicin

Nanomedicine, 2015
To test the efficacy and toxicity of exosomal doxorubicin (exoDOX) compared with free doxorubicin.The cytotoxic effects of exoDOX were tested in vitro and in nude mice by measuring the tumor volume. The toxic effects were evaluated by measuring the bodyweight and through histopathologic analyses.
TOFFOLI, GIUSEPPE, Hadla, Mohamad, Corona, Giuseppe, Caligiuri, Isabella, PALAZZOLO, STEFANO, SEMERARO, SABRINA, GAMINI, AMELIA, Canzonieri, Vincenzo, Rizzolio, Flavio   +8 more
openaire   +3 more sources

miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. [PDF]

, 2012
Acquired resistance to classical chemotherapeutics is a major obstacle in cancer treatment. Doxorubicin is frequently used in breast cancer therapy either as single-agent or in combination with other drugs like docetaxel and cyclophosphamide.
Oak, Prajakta S., Prajakta S. Oak (115995), Florian Kopp, Andreas Roidl, Kopp, Florian, Roidl, Andreas, Prajakta S Oak, Florian Kopp (115988), Ernst Wagner (60760), Andreas Roidl (116002), Wagner, Ernst, Ernst Wagner   +11 more
core   +2 more sources

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

BMC Cancer, 2018
Background Olaratumab is a platelet-derived growth factor receptor-α (PDGFRα)-targeting monoclonal antibody blocking PDGFRα signaling. PDGFRα expression is associated with a more aggressive phenotype and poor ovarian cancer outcomes.
William P. McGuire, Richard T. Penson, Martin Gore, Antonio Casado Herraez, Patrick Peterson, Ashwin Shahir, Robert Ilaria   +6 more
doaj   +1 more source

Temozolomid und pegyliertes liposomales Doxorubicin in Kombination mit Strahlentherapie in der Ersttherapie von Patienten mit Glioblastom WHO Grad IV – eine Phase I/II – Studie (RNOP – 09) [PDF]

, 2011
Hintergrund: Die EORTC26981/NCIC-CE.3-Studie hatte 2005 zur Etablierung eines neuen Standard-Therapieregimes für das Glioblastom geführt. Obwohl sich Temozolomid hierbei als wirksames Agens gezeigt hatte, bleibt die Prognose für diese Entität sehr ...
Schmid, Christina
core   +1 more source